{"Q": 1, "answer": "no", "rationale": "The segment does not contain an intensifier or comparative adjective directly modifying a risk-adjective.", "method": "llm_batch", "batch_id": "batch_1_3232", "batch_size": 260, "batch_pos": 127, "statement_text": "The deal secures up to 665,000 doses from vaccine manufacturer CSL Seqirus and includes an option for a further 40 million vaccines for a maximum of four years.", "article_id": 1683}
{"Q": 2, "answer": "no", "rationale": "The segment reports factual details of a deal using neutral language.", "method": "llm_batch", "batch_id": "batch_2_15988", "batch_size": 260, "batch_pos": 126, "statement_text": "The deal secures up to 665,000 doses from vaccine manufacturer CSL Seqirus and includes an option for a further 40 million vaccines for a maximum of four years.", "article_id": 1683}
{"Q": 3, "answer": "no", "rationale": "The segment describes a deal and quantity, not a moderate verb paired with impact.", "method": "llm_batch", "batch_id": "batch_3_18080", "batch_size": 260, "batch_pos": 119, "statement_text": "The deal secures up to 665,000 doses from vaccine manufacturer CSL Seqirus and includes an option for a further 40 million vaccines for a maximum of four years.", "article_id": 1683}
{"Q": 4, "answer": "no", "rationale": "The segment does not contain a loaded rhetorical question.", "method": "llm_batch", "batch_id": "batch_4_14112", "batch_size": 260, "batch_pos": 119, "statement_text": "The deal secures up to 665,000 doses from vaccine manufacturer CSL Seqirus and includes an option for a further 40 million vaccines for a maximum of four years.", "article_id": 1683}
{"Q": 5, "answer": "no", "rationale": "The segment reports details of a vaccine deal, which is preparedness, but lacks explicit calming language or required keywords linking it to public safety.", "method": "llm_batch", "batch_id": "batch_5_18376", "batch_size": 260, "batch_pos": 117, "statement_text": "The deal secures up to 665,000 doses from vaccine manufacturer CSL Seqirus and includes an option for a further 40 million vaccines for a maximum of four years.", "article_id": 1683}
{"Q": 6, "answer": "no", "rationale": "The segment does not contain a minimiser used in conjunction with a scale contrast.", "method": "llm_batch", "batch_id": "batch_6_4040", "batch_size": 260, "batch_pos": 114, "statement_text": "The deal secures up to 665,000 doses from vaccine manufacturer CSL Seqirus and includes an option for a further 40 million vaccines for a maximum of four years.", "article_id": 1683}
{"Q": 7, "answer": "no", "rationale": "The segment does not contain a bare negation.", "method": "llm_batch", "batch_id": "batch_7_7536", "batch_size": 260, "batch_pos": 114, "statement_text": "The deal secures up to 665,000 doses from vaccine manufacturer CSL Seqirus and includes an option for a further 40 million vaccines for a maximum of four years.", "article_id": 1683}
{"Q": 8, "answer": "yes", "rationale": "Describes securing vaccine doses (stockpiling/preparedness).", "method": "llm_batch", "batch_id": "batch_8_14568", "batch_size": 260, "batch_pos": 98, "statement_text": "The deal secures up to 665,000 doses from vaccine manufacturer CSL Seqirus and includes an option for a further 40 million vaccines for a maximum of four years.", "article_id": 1683}
